JP5823094B2 - 絹タンパク質を使用する組織の治療方法及び組成物 - Google Patents
絹タンパク質を使用する組織の治療方法及び組成物 Download PDFInfo
- Publication number
- JP5823094B2 JP5823094B2 JP2009539265A JP2009539265A JP5823094B2 JP 5823094 B2 JP5823094 B2 JP 5823094B2 JP 2009539265 A JP2009539265 A JP 2009539265A JP 2009539265 A JP2009539265 A JP 2009539265A JP 5823094 B2 JP5823094 B2 JP 5823094B2
- Authority
- JP
- Japan
- Prior art keywords
- polyethylene glycol
- carrier
- silk protein
- block copolymer
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000004169 proteins and genes Human genes 0.000 title claims description 112
- 108090000623 proteins and genes Proteins 0.000 title claims description 112
- 238000000034 method Methods 0.000 title claims description 74
- 239000000203 mixture Substances 0.000 title claims description 66
- 229920001223 polyethylene glycol Polymers 0.000 claims description 126
- 239000002202 Polyethylene glycol Substances 0.000 claims description 109
- 229920000642 polymer Polymers 0.000 claims description 69
- 229920001400 block copolymer Polymers 0.000 claims description 62
- 239000000243 solution Substances 0.000 claims description 54
- 239000011159 matrix material Substances 0.000 claims description 42
- 239000012620 biological material Substances 0.000 claims description 40
- 230000005540 biological transmission Effects 0.000 claims description 40
- 239000007864 aqueous solution Substances 0.000 claims description 34
- 239000002131 composite material Substances 0.000 claims description 24
- 229920001059 synthetic polymer Polymers 0.000 claims description 24
- 238000001879 gelation Methods 0.000 claims description 19
- 230000000269 nucleophilic effect Effects 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 19
- 239000000872 buffer Substances 0.000 claims description 18
- 239000006285 cell suspension Substances 0.000 claims description 16
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 15
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 13
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 13
- 229920002971 Heparan sulfate Polymers 0.000 claims description 13
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 13
- 108010076876 Keratins Proteins 0.000 claims description 13
- 102000011782 Keratins Human genes 0.000 claims description 13
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 13
- 239000002243 precursor Substances 0.000 claims description 13
- 239000007853 buffer solution Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 5
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical group ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 3
- 229920002554 vinyl polymer Polymers 0.000 claims 3
- 230000001588 bifunctional effect Effects 0.000 claims 1
- 238000003682 fluorination reaction Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 98
- 239000000499 gel Substances 0.000 description 44
- 210000004027 cell Anatomy 0.000 description 31
- 239000003102 growth factor Substances 0.000 description 24
- 239000000835 fiber Substances 0.000 description 22
- 239000000017 hydrogel Substances 0.000 description 19
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 18
- 208000010125 myocardial infarction Diseases 0.000 description 18
- 238000002347 injection Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 13
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 13
- 108010049003 Fibrinogen Proteins 0.000 description 12
- 102000008946 Fibrinogen Human genes 0.000 description 12
- 150000003573 thiols Chemical class 0.000 description 12
- 229920001436 collagen Polymers 0.000 description 11
- 229940012952 fibrinogen Drugs 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 229920001410 Microfiber Polymers 0.000 description 10
- 108090000190 Thrombin Proteins 0.000 description 10
- 239000003658 microfiber Substances 0.000 description 10
- 239000007790 solid phase Substances 0.000 description 10
- 229960004072 thrombin Drugs 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 206010061216 Infarction Diseases 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000007574 infarction Effects 0.000 description 9
- 239000011859 microparticle Substances 0.000 description 9
- 210000000130 stem cell Anatomy 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 8
- 229920002549 elastin Polymers 0.000 description 8
- 229920002674 hyaluronan Polymers 0.000 description 8
- 229960003160 hyaluronic acid Drugs 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 108010022355 Fibroins Proteins 0.000 description 7
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 7
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 7
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 7
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 7
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 7
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 7
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000008439 repair process Effects 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 6
- 239000011258 core-shell material Substances 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 108010073385 Fibrin Proteins 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 5
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 239000012062 aqueous buffer Substances 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 210000001612 chondrocyte Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000001523 electrospinning Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 229950003499 fibrin Drugs 0.000 description 5
- 210000005087 mononuclear cell Anatomy 0.000 description 5
- 239000012038 nucleophile Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000007634 remodeling Methods 0.000 description 5
- PVVTWNMXEHROIA-UHFFFAOYSA-N 2-(3-hydroxypropyl)-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(CCCO)=NC(=O)C2=C1 PVVTWNMXEHROIA-UHFFFAOYSA-N 0.000 description 4
- 241000255789 Bombyx mori Species 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 239000003929 acidic solution Substances 0.000 description 4
- 238000000429 assembly Methods 0.000 description 4
- 230000000712 assembly Effects 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 210000004413 cardiac myocyte Anatomy 0.000 description 4
- 210000000845 cartilage Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000006482 condensation reaction Methods 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 239000011162 core material Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 229920001002 functional polymer Polymers 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 239000008177 pharmaceutical agent Substances 0.000 description 4
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- -1 thiol anion Chemical class 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 206010019909 Hernia Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000006845 Michael addition reaction Methods 0.000 description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
- 239000004952 Polyamide Substances 0.000 description 3
- 238000007259 addition reaction Methods 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000010339 dilation Effects 0.000 description 3
- 229940126534 drug product Drugs 0.000 description 3
- 239000012039 electrophile Substances 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 210000005240 left ventricle Anatomy 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229920001982 poly(ester urethane) Polymers 0.000 description 3
- 229920002647 polyamide Polymers 0.000 description 3
- 229920001610 polycaprolactone Polymers 0.000 description 3
- 229920000098 polyolefin Polymers 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 210000001562 sternum Anatomy 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000009772 tissue formation Effects 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 2
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 2
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 2
- 108010013296 Sericins Proteins 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 239000002121 nanofiber Substances 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001432 poly(L-lactide) Polymers 0.000 description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
- 229920000671 polyethylene glycol diacrylate Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000036573 scar formation Effects 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 210000002417 xiphoid bone Anatomy 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GGZZISOUXJHYOY-UHFFFAOYSA-N 8-amino-4-hydroxynaphthalene-2-sulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C2C(N)=CC=CC2=C1O GGZZISOUXJHYOY-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 241000193935 Araneus diadematus Species 0.000 description 1
- 101100170173 Caenorhabditis elegans del-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- FBPFZTCFMRRESA-ZXXMMSQZSA-N D-iditol Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-ZXXMMSQZSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000013875 Heart injury Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102100039064 Interleukin-3 Human genes 0.000 description 1
- 102100026236 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 241000238902 Nephila clavipes Species 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- 101000882917 Penaeus paulensis Hemolymph clottable protein Proteins 0.000 description 1
- 229920006022 Poly(L-lactide-co-glycolide)-b-poly(ethylene glycol) Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102100031372 Thymidine phosphorylase Human genes 0.000 description 1
- 108700023160 Thymidine phosphorylases Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- VRGWBRLULZUWAJ-XFFXIZSCSA-N [(2s)-2-[(1r,3z,5s,8z,12z,15s)-5,17-dihydroxy-4,8,12,15-tetramethyl-16-oxo-18-bicyclo[13.3.0]octadeca-3,8,12,17-tetraenyl]propyl] acetate Chemical compound C1\C=C(C)/CC\C=C(C)/CC[C@H](O)\C(C)=C/C[C@@H]2C([C@@H](COC(C)=O)C)=C(O)C(=O)[C@]21C VRGWBRLULZUWAJ-XFFXIZSCSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 125000004386 diacrylate group Chemical group 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229920000359 diblock copolymer Polymers 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- VRGWBRLULZUWAJ-UHFFFAOYSA-N fusaproliferin Natural products C1C=C(C)CCC=C(C)CCC(O)C(C)=CCC2C(C(COC(C)=O)C)=C(O)C(=O)C21C VRGWBRLULZUWAJ-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 229920000070 poly-3-hydroxybutyrate Polymers 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229930185346 proliferin Natural products 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000004683 skeletal myoblast Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229910000679 solder Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 229940033618 tisseel Drugs 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/48—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Dispersion Chemistry (AREA)
- Neurosurgery (AREA)
- Developmental Biology & Embryology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Polymers & Plastics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/566,643 | 2006-12-04 | ||
| US11/566,643 US8192760B2 (en) | 2006-12-04 | 2006-12-04 | Methods and compositions for treating tissue using silk proteins |
| PCT/US2007/024158 WO2008069919A2 (en) | 2006-12-04 | 2007-11-16 | Methods & compositions for treating tissue using silk proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014076351A Division JP5853045B2 (ja) | 2006-12-04 | 2014-04-02 | 絹タンパク質を使用する組織の治療方法及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010511426A JP2010511426A (ja) | 2010-04-15 |
| JP2010511426A5 JP2010511426A5 (enExample) | 2011-01-13 |
| JP5823094B2 true JP5823094B2 (ja) | 2015-11-25 |
Family
ID=39476093
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009539265A Expired - Fee Related JP5823094B2 (ja) | 2006-12-04 | 2007-11-16 | 絹タンパク質を使用する組織の治療方法及び組成物 |
| JP2014076351A Expired - Fee Related JP5853045B2 (ja) | 2006-12-04 | 2014-04-02 | 絹タンパク質を使用する組織の治療方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014076351A Expired - Fee Related JP5853045B2 (ja) | 2006-12-04 | 2014-04-02 | 絹タンパク質を使用する組織の治療方法及び組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (4) | US8192760B2 (enExample) |
| EP (1) | EP2099509B1 (enExample) |
| JP (2) | JP5823094B2 (enExample) |
| WO (1) | WO2008069919A2 (enExample) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6702744B2 (en) | 2001-06-20 | 2004-03-09 | Advanced Cardiovascular Systems, Inc. | Agents that stimulate therapeutic angiogenesis and techniques and devices that enable their delivery |
| US20110009960A1 (en) * | 2001-11-16 | 2011-01-13 | Allergan, Inc. | Prosthetic fabric structure |
| US6902932B2 (en) * | 2001-11-16 | 2005-06-07 | Tissue Regeneration, Inc. | Helically organized silk fibroin fiber bundles for matrices in tissue engineering |
| US8608661B1 (en) | 2001-11-30 | 2013-12-17 | Advanced Cardiovascular Systems, Inc. | Method for intravascular delivery of a treatment agent beyond a blood vessel wall |
| US7361368B2 (en) | 2002-06-28 | 2008-04-22 | Advanced Cardiovascular Systems, Inc. | Device and method for combining a treatment agent and a gel |
| US8821473B2 (en) | 2003-04-15 | 2014-09-02 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
| US8383158B2 (en) | 2003-04-15 | 2013-02-26 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
| US8187621B2 (en) | 2005-04-19 | 2012-05-29 | Advanced Cardiovascular Systems, Inc. | Methods and compositions for treating post-myocardial infarction damage |
| US20080125745A1 (en) | 2005-04-19 | 2008-05-29 | Shubhayu Basu | Methods and compositions for treating post-cardial infarction damage |
| US8828433B2 (en) * | 2005-04-19 | 2014-09-09 | Advanced Cardiovascular Systems, Inc. | Hydrogel bioscaffoldings and biomedical device coatings |
| US9539410B2 (en) | 2005-04-19 | 2017-01-10 | Abbott Cardiovascular Systems Inc. | Methods and compositions for treating post-cardial infarction damage |
| WO2007117687A2 (en) | 2006-04-06 | 2007-10-18 | Nupathe Inc. | Implants for the treatment of dopamine associated states |
| US7732190B2 (en) * | 2006-07-31 | 2010-06-08 | Advanced Cardiovascular Systems, Inc. | Modified two-component gelation systems, methods of use and methods of manufacture |
| US9242005B1 (en) | 2006-08-21 | 2016-01-26 | Abbott Cardiovascular Systems Inc. | Pro-healing agent formulation compositions, methods and treatments |
| US8741326B2 (en) | 2006-11-17 | 2014-06-03 | Abbott Cardiovascular Systems Inc. | Modified two-component gelation systems, methods of use and methods of manufacture |
| US9005672B2 (en) | 2006-11-17 | 2015-04-14 | Abbott Cardiovascular Systems Inc. | Methods of modifying myocardial infarction expansion |
| US8192760B2 (en) | 2006-12-04 | 2012-06-05 | Abbott Cardiovascular Systems Inc. | Methods and compositions for treating tissue using silk proteins |
| US9301826B2 (en) | 2008-02-18 | 2016-04-05 | Covidien Lp | Lock bar spring and clip for implant deployment device |
| US8317808B2 (en) | 2008-02-18 | 2012-11-27 | Covidien Lp | Device and method for rolling and inserting a prosthetic patch into a body cavity |
| US9398944B2 (en) | 2008-02-18 | 2016-07-26 | Covidien Lp | Lock bar spring and clip for implant deployment device |
| WO2009104182A2 (en) | 2008-02-18 | 2009-08-27 | Polytouch Medical Ltd | A device and method for deploying and attaching a patch to a biological tissue |
| US9833240B2 (en) | 2008-02-18 | 2017-12-05 | Covidien Lp | Lock bar spring and clip for implant deployment device |
| US9393093B2 (en) | 2008-02-18 | 2016-07-19 | Covidien Lp | Clip for implant deployment device |
| US9044235B2 (en) | 2008-02-18 | 2015-06-02 | Covidien Lp | Magnetic clip for implant deployment device |
| US9034002B2 (en) | 2008-02-18 | 2015-05-19 | Covidien Lp | Lock bar spring and clip for implant deployment device |
| US8758373B2 (en) | 2008-02-18 | 2014-06-24 | Covidien Lp | Means and method for reversibly connecting a patch to a patch deployment device |
| US9393002B2 (en) | 2008-02-18 | 2016-07-19 | Covidien Lp | Clip for implant deployment device |
| US8808314B2 (en) | 2008-02-18 | 2014-08-19 | Covidien Lp | Device and method for deploying and attaching an implant to a biological tissue |
| US9089700B2 (en) | 2008-08-11 | 2015-07-28 | Cibiem, Inc. | Systems and methods for treating dyspnea, including via electrical afferent signal blocking |
| WO2010025176A2 (en) * | 2008-08-28 | 2010-03-04 | Organogenesis, Inc. | Mcp-1 delivery system |
| WO2010046893A1 (en) | 2008-10-20 | 2010-04-29 | Polytouch Medical Ltd. | A device for attaching a patch to a biological tissue |
| FR2937974B1 (fr) * | 2008-10-30 | 2013-01-11 | Univ Bordeaux 1 | Copolymeres a blocs a base de polysaccharide et de polypeptide, les vesicules constituees de ces copolymeres et leur utilisation |
| US8323352B2 (en) * | 2008-11-20 | 2012-12-04 | Lifecell Corporation | Method for treatment and prevention of parastomal hernias |
| US9204953B2 (en) | 2008-12-15 | 2015-12-08 | Allergan, Inc. | Biocompatible surgical scaffold with varying stretch |
| US9308070B2 (en) * | 2008-12-15 | 2016-04-12 | Allergan, Inc. | Pliable silk medical device |
| US9326840B2 (en) | 2008-12-15 | 2016-05-03 | Allergan, Inc. | Prosthetic device and method of manufacturing the same |
| US9204954B2 (en) * | 2008-12-15 | 2015-12-08 | Allergan, Inc. | Knitted scaffold with diagonal yarn |
| JP5653931B2 (ja) | 2008-12-15 | 2015-01-14 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 補綴デバイスおよびその製作方法 |
| US20110111031A1 (en) * | 2009-04-20 | 2011-05-12 | Guang-Liang Jiang | Drug Delivery Platforms Comprising Silk Fibroin Hydrogels and Uses Thereof |
| US8420077B2 (en) * | 2009-04-20 | 2013-04-16 | Allergan, Inc. | Silk fibroin hydrogels and uses thereof |
| US20110189292A1 (en) * | 2009-04-20 | 2011-08-04 | Allergan, Inc. | Dermal fillers comprising silk fibroin hydrogels and uses thereof |
| US20110052695A1 (en) * | 2009-04-20 | 2011-03-03 | Allergan, Inc. | Drug delivery platforms comprising silk fibroin hydrogels and uses thereof |
| CA2769707A1 (en) | 2009-08-17 | 2011-02-24 | Tyco Healthcare Group Lp | Articulating patch deployment device and method of use |
| CA2769666C (en) | 2009-08-17 | 2018-02-13 | Arie Levy | Means and method for reversibly connecting an implant to a deployment device |
| AU2010292237A1 (en) * | 2009-09-11 | 2012-04-05 | Allergan, Inc. | Prosthetic device and method of manufacturing the same |
| US8968785B2 (en) * | 2009-10-02 | 2015-03-03 | Covidien Lp | Surgical compositions |
| BR112012011585A2 (pt) * | 2009-11-02 | 2015-10-13 | Nupathe Inc | métodos para tratamento de doença de parkinson |
| ES2811027T3 (es) * | 2010-02-19 | 2021-03-10 | Lifecell Corp | Dispositivos para el tratamiento de la pared abdominal |
| US9758558B2 (en) | 2010-04-01 | 2017-09-12 | Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College | Whey protein isolate hydrogels and their uses |
| WO2012009682A2 (en) * | 2010-07-15 | 2012-01-19 | The Board Of Trustees Of The Leland Stanford Junior University | Elastic substrates and methods of use in cell manipulation and culture |
| US8524215B2 (en) | 2010-08-02 | 2013-09-03 | Janssen Biotech, Inc. | Absorbable PEG-based hydrogels |
| EP2611473A4 (en) * | 2010-09-01 | 2014-08-13 | Tufts College | SILK FIBROIN AND POLYETHYLENE GLYCOL BIOMATERIALS |
| EP2619356A4 (en) * | 2010-09-22 | 2014-04-09 | Univ Virginia Commonwealth | PREPARATION WITH A HIGH SHARE OF FIBER MATRICES ON A GROWTH FACTOR BASIS FOR TISSUE ENGINEERING, GROWTH FACTOR LEAKAGE AND WOUND HEALING |
| US20140329314A1 (en) * | 2011-03-29 | 2014-11-06 | Christopher O'Sullivan | Enriched populations of cardiomyocyte lineage cells from pluripotent stem cells |
| CN102174203B (zh) * | 2011-03-29 | 2012-12-26 | 苏州大学 | 一种丝素蛋白/共聚物水凝胶的制备方法 |
| EP3549615B1 (en) | 2011-12-20 | 2020-12-16 | LifeCell Corporation | Sheet tissue products |
| EP3501558B1 (en) | 2011-12-20 | 2020-11-25 | LifeCell Corporation | Flowable tissue products |
| EP3797801A1 (en) | 2012-01-24 | 2021-03-31 | LifeCell Corporation | Elongated tissue matrices |
| CN104519817B (zh) | 2012-04-24 | 2017-11-10 | 西比姆公司 | 用于颈动脉体摘除的血管内导管和方法 |
| BR112014026088B1 (pt) | 2012-04-24 | 2019-11-05 | Lifecell Corp | produto de tratamento de tecidos |
| US10322185B2 (en) * | 2012-04-25 | 2019-06-18 | Hitachi Chemical Company, Ltd. | Controlled release carrier for drugs containing silk fibroin porous material |
| US9402677B2 (en) | 2012-06-01 | 2016-08-02 | Cibiem, Inc. | Methods and devices for cryogenic carotid body ablation |
| EP2854681A4 (en) | 2012-06-01 | 2016-02-17 | Cibiem Inc | PERCUTANEOUS METHODS AND DEVICES FOR CAROTIDE BODY ABLATION |
| WO2014005155A1 (en) | 2012-06-30 | 2014-01-03 | Cibiem, Inc. | Carotid body ablation via directed energy |
| US20140072611A1 (en) | 2012-09-07 | 2014-03-13 | Fibrocell Technologies, Inc. | Methods and Compositions for Treating Post-Cardial Infarction Damage |
| WO2014132262A1 (en) * | 2013-02-28 | 2014-09-04 | Ramot At Tel-Aviv University Ltd. | Peptide-based hydrogel particles and uses thereof |
| WO2014138190A1 (en) * | 2013-03-06 | 2014-09-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Cell-based compositions, cell-based bandage devices and systems and methods of treatment therewith |
| US20160193106A1 (en) * | 2013-08-20 | 2016-07-07 | Wake Forest University Health Sciences | Tissue repair devices utilizing self-assembled materials |
| US9512279B2 (en) * | 2013-12-18 | 2016-12-06 | Universite Cegy-Pontoise | Interpenetrating polymer network |
| EP3116408B1 (en) | 2014-03-12 | 2018-12-19 | Cibiem, Inc. | Ultrasound ablation catheter |
| WO2015157681A1 (en) * | 2014-04-11 | 2015-10-15 | Vitruvian Medical Devices, Inc. | Microparticles for wound treatment |
| EA035551B1 (ru) | 2014-12-02 | 2020-07-06 | Силк Терапьютикс, Инк. | Изделие |
| CN108135975A (zh) | 2015-07-14 | 2018-06-08 | 丝绸医疗公司 | 丝性能服装和产品及其制备方法 |
| KR101637883B1 (ko) * | 2015-09-30 | 2016-07-21 | 선바이오(주) | 폴리에틸렌글리콜 수화젤 주사제 |
| EP3373870A4 (en) | 2015-11-12 | 2019-07-10 | University Of Virginia Patent Foundation | COMPOSITIONS AND METHODS FOR VAS OCCLUSAL CONSUMER PREVENTION AND THEIR REVERSAL |
| CN106075575A (zh) * | 2016-06-28 | 2016-11-09 | 福州大学 | 一种用于膝骨性关节炎软骨修复的复合材料及其制备方法 |
| US12383421B2 (en) | 2017-01-05 | 2025-08-12 | Contraline, Inc. | Contraceptive devices |
| IT201700036930A1 (it) * | 2017-04-04 | 2018-10-04 | Silk Biomaterials S R L | Sistema che comprende idrogel e nanofibre |
| CN110944689B (zh) | 2017-06-07 | 2022-12-09 | 施菲姆德控股有限责任公司 | 血管内流体运动设备、系统和使用方法 |
| US11390988B2 (en) | 2017-09-27 | 2022-07-19 | Evolved By Nature, Inc. | Silk coated fabrics and products and methods of preparing the same |
| EP3710076B1 (en) | 2017-11-13 | 2023-12-27 | Shifamed Holdings, LLC | Intravascular fluid movement devices, systems, and methods of use |
| WO2019152875A1 (en) | 2018-02-01 | 2019-08-08 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of use and manufacture |
| WO2020028537A1 (en) | 2018-07-31 | 2020-02-06 | Shifamed Holdings, Llc | Intravascaular blood pumps and methods of use |
| US12220570B2 (en) | 2018-10-05 | 2025-02-11 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of use |
| IL282609B2 (en) * | 2018-10-26 | 2025-05-01 | St Oncologico Veneto Iov Irccs | Hyaluronic acid as a natural adjuvant for protein and peptide-based vaccines |
| EP3996797A4 (en) | 2019-07-12 | 2023-08-02 | Shifamed Holdings, LLC | INTRAVASCULAR BLOOD PUMPS AND METHOD OF USE AND METHOD OF MAKING |
| US11654275B2 (en) | 2019-07-22 | 2023-05-23 | Shifamed Holdings, Llc | Intravascular blood pumps with struts and methods of use and manufacture |
| EP4010046A4 (en) | 2019-08-07 | 2023-08-30 | Calomeni, Michael | Catheter blood pumps and collapsible pump housings |
| WO2021062260A1 (en) | 2019-09-25 | 2021-04-01 | Shifamed Holdings, Llc | Catheter blood pumps and collapsible blood conduits |
| WO2021062270A1 (en) | 2019-09-25 | 2021-04-01 | Shifamed Holdings, Llc | Catheter blood pumps and collapsible pump housings |
| WO2021062265A1 (en) | 2019-09-25 | 2021-04-01 | Shifamed Holdings, Llc | Intravascular blood pump systems and methods of use and control thereof |
| WO2021119478A1 (en) | 2019-12-11 | 2021-06-17 | Shifamed Holdings, Llc | Descending aorta and vena cava blood pumps |
| EP4326230A4 (en) * | 2021-04-21 | 2025-08-13 | Ohio State Innovation Foundation | NANOFIBER AND NANOWHITE-BASED TRANSFECTION PLATFORMS FOR MASS ELECTROPORATION |
| US20250065011A1 (en) * | 2021-12-23 | 2025-02-27 | Dsm Ip Assets B.V. | Synthetic biopolymers and their use in compositions for tissue repair |
| WO2024184189A1 (en) | 2023-03-03 | 2024-09-12 | Danmarks Tekniske Universitet | Monodisperse nanofibrous microparticles for delivery of one or more active substances |
Family Cites Families (283)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2194144B (en) | 1986-08-22 | 1990-04-25 | American Cyanamid Co | Stable pharmaceutical gel preparation |
| US2512569A (en) | 1947-09-26 | 1950-06-20 | Jacob A Saffir | Hypodermic needle |
| US3144868A (en) | 1960-10-21 | 1964-08-18 | Mario E Jascalevich | Drainage and feeding cannulae |
| US3584624A (en) | 1969-02-24 | 1971-06-15 | Vincent L De Ciutiis | Flexible intravenous catheter provided with cutting tip means |
| US3780733A (en) | 1972-07-24 | 1973-12-25 | Manzor M Martinez | Catheter |
| US3890976A (en) | 1972-10-26 | 1975-06-24 | Medical Products Corp | Catheter tip assembly |
| US3804097A (en) | 1972-12-14 | 1974-04-16 | P Rudie | Method of irrigating and treating an abcess |
| US6436135B1 (en) | 1974-10-24 | 2002-08-20 | David Goldfarb | Prosthetic vascular graft |
| US4141973A (en) | 1975-10-17 | 1979-02-27 | Biotrics, Inc. | Ultrapure hyaluronic acid and the use thereof |
| JPS60126170A (ja) | 1983-12-14 | 1985-07-05 | テルモ株式会社 | カテ−テルとその製造方法 |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US4617186A (en) | 1984-12-28 | 1986-10-14 | Alcon Laboratories, Inc. | Sustained release drug delivery system utilizing bioadhesive polymers |
| US4794931A (en) | 1986-02-28 | 1989-01-03 | Cardiovascular Imaging Systems, Inc. | Catheter apparatus, system and method for intravascular two-dimensional ultrasonography |
| US5000185A (en) | 1986-02-28 | 1991-03-19 | Cardiovascular Imaging Systems, Inc. | Method for intravascular two-dimensional ultrasonography and recanalization |
| US5026350A (en) | 1986-10-09 | 1991-06-25 | Hakko Electric Machine Works Co., Ltd. | Set of double needles for injecting liquid medicine |
| JPS6485272A (en) * | 1986-12-10 | 1989-03-30 | Ajinomoto Kk | Adhesive |
| CH673117A5 (enExample) | 1986-12-10 | 1990-02-15 | Ajinomoto Kk | |
| US5606019A (en) * | 1987-10-29 | 1997-02-25 | Protien Polymer Technologies, Inc. | Synthetic protein as implantables |
| FR2627984B1 (fr) | 1988-03-03 | 1990-08-17 | Sanofi Sa | Composition pulverulente a base d'alginate pour empreintes dentaires |
| US5372138A (en) | 1988-03-21 | 1994-12-13 | Boston Scientific Corporation | Acousting imaging catheters and the like |
| US5588432A (en) | 1988-03-21 | 1996-12-31 | Boston Scientific Corporation | Catheters for imaging, sensing electrical potentials, and ablating tissue |
| US5116317A (en) | 1988-06-16 | 1992-05-26 | Optimed Technologies, Inc. | Angioplasty catheter with integral fiber optic assembly |
| US5634946A (en) | 1988-08-24 | 1997-06-03 | Focal, Inc. | Polymeric endoluminal paving process |
| AU4191989A (en) | 1988-08-24 | 1990-03-23 | Marvin J. Slepian | Biodegradable polymeric endoluminal sealing |
| US5575815A (en) | 1988-08-24 | 1996-11-19 | Endoluminal Therapeutics, Inc. | Local polymeric gel therapy |
| US5843156A (en) | 1988-08-24 | 1998-12-01 | Endoluminal Therapeutics, Inc. | Local polymeric gel cellular therapy |
| US5092848A (en) | 1988-10-13 | 1992-03-03 | Deciutiis Vincent L | Intravenous catheter with built-in cutting tip and method for making the same |
| ATE161879T1 (de) * | 1988-11-09 | 1998-01-15 | Protein Polymer Tech Inc | Funktionelles, durch ein rekombinantes verfahren hergestelltes synthetisches proteinpolymer |
| US5162430A (en) | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
| JPH0662678B2 (ja) * | 1988-11-28 | 1994-08-17 | 電気化学工業株式会社 | ヒアルロン酸固定化蛋白質及びその製造方法 |
| US5049130A (en) | 1988-12-23 | 1991-09-17 | Cardiovascular Imaging Systems, Inc. | System and method for pressure filling of catheters |
| DE3908183C5 (de) | 1989-03-14 | 2005-01-05 | Kiekert Ag | Kraftfahrzeug-Türverschluß |
| JPH02145600U (enExample) | 1989-05-15 | 1990-12-11 | ||
| US5109859A (en) | 1989-10-04 | 1992-05-05 | Beth Israel Hospital Association | Ultrasound guided laser angioplasty |
| US5024234A (en) | 1989-10-17 | 1991-06-18 | Cardiovascular Imaging Systems, Inc. | Ultrasonic imaging catheter with guidewire channel |
| US5485486A (en) | 1989-11-07 | 1996-01-16 | Qualcomm Incorporated | Method and apparatus for controlling transmission power in a CDMA cellular mobile telephone system |
| WO1991007154A1 (en) | 1989-11-13 | 1991-05-30 | President And Fellows Of Harvard College | EXTRALUMINAL REGULATION OF THE GROWTH AND REPAIR OF TUBULAR STRUCTURES ιIN VIVO |
| US5674192A (en) | 1990-12-28 | 1997-10-07 | Boston Scientific Corporation | Drug delivery |
| US5811533A (en) | 1990-06-11 | 1998-09-22 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF) |
| FR2668698B1 (fr) | 1990-11-06 | 1997-06-06 | Ethnor | Instrument chirurgical formant trocart. |
| US5202745A (en) | 1990-11-07 | 1993-04-13 | Hewlett-Packard Company | Polarization independent optical coherence-domain reflectometry |
| ATE157269T1 (de) | 1990-12-17 | 1997-09-15 | Cardiovascular Imaging Systems | Vaskularer katheter mit einem ein niedriges profil aufweisenden distalen ende |
| US5171217A (en) | 1991-02-28 | 1992-12-15 | Indiana University Foundation | Method for delivery of smooth muscle cell inhibitors |
| US5465147A (en) | 1991-04-29 | 1995-11-07 | Massachusetts Institute Of Technology | Method and apparatus for acquiring images using a ccd detector array and no transverse scanner |
| DE69227902T3 (de) | 1991-04-29 | 2010-04-22 | Massachusetts Institute Of Technology, Cambridge | Vorrichtung für optische abbildung und messung |
| US6134003A (en) | 1991-04-29 | 2000-10-17 | Massachusetts Institute Of Technology | Method and apparatus for performing optical measurements using a fiber optic imaging guidewire, catheter or endoscope |
| SE9101853D0 (sv) * | 1991-06-17 | 1991-06-17 | Jonas Wadstroem | Improved tissue ashesive |
| US5270300A (en) | 1991-09-06 | 1993-12-14 | Robert Francis Shaw | Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone |
| US5291267A (en) | 1992-01-22 | 1994-03-01 | Hewlett-Packard Company | Optical low-coherence reflectometry using optical amplification |
| DE69333482T2 (de) | 1992-02-21 | 2005-03-24 | Boston Scientific Ltd., Barbados | Katheter zur Bilderzeugung mittels Ultraschall |
| US6231881B1 (en) | 1992-02-24 | 2001-05-15 | Anton-Lewis Usala | Medium and matrix for long-term proliferation of cells |
| US5573934A (en) | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
| MX9301823A (es) | 1992-03-30 | 1994-01-31 | Alza Corp | Composicion para el suministro de liberacion controlado de un agente biologicamente activo. |
| US5306250A (en) | 1992-04-02 | 1994-04-26 | Indiana University Foundation | Method and apparatus for intravascular drug delivery |
| US5336252A (en) | 1992-06-22 | 1994-08-09 | Cohen Donald M | System and method for implanting cardiac electrical leads |
| US5365325A (en) | 1992-08-10 | 1994-11-15 | Hitachi, Ltd. | Method of multi-color recording using electro-photography process and apparatus therefor wherein mixed colors generation is prevented |
| US5672153A (en) | 1992-08-12 | 1997-09-30 | Vidamed, Inc. | Medical probe device and method |
| DE4235506A1 (de) | 1992-10-21 | 1994-04-28 | Bavaria Med Tech | Katheter zur Injektion von Arzneimitteln |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6689608B1 (en) | 1993-02-01 | 2004-02-10 | Massachusetts Institute Of Technology | Porous biodegradable polymeric materials for cell transplantation |
| US5709854A (en) | 1993-04-30 | 1998-01-20 | Massachusetts Institute Of Technology | Tissue formation by injecting a cell-polymeric solution that gels in vivo |
| EP2025353A2 (en) | 1993-04-30 | 2009-02-18 | Massachusetts Institute of Technology | Injectable polysaccharide-cell compositions |
| US5437632A (en) | 1993-06-02 | 1995-08-01 | Target Therapeutics, Inc. | Variable stiffness balloon catheter |
| US5725551A (en) | 1993-07-26 | 1998-03-10 | Myers; Gene | Method and apparatus for arteriotomy closure |
| US5527322A (en) | 1993-11-08 | 1996-06-18 | Perclose, Inc. | Device and method for suturing of internal puncture sites |
| JP2833456B2 (ja) | 1993-11-22 | 1998-12-09 | 株式会社東芝 | 体内挿入型超音波検査装置 |
| US5380292A (en) | 1993-12-22 | 1995-01-10 | Wilson-Cook Medical, Inc. | Gastrointestinal needle mechanism |
| US5795331A (en) | 1994-01-24 | 1998-08-18 | Micro Therapeutics, Inc. | Balloon catheter for occluding aneurysms of branch vessels |
| FR2715855A1 (fr) | 1994-02-10 | 1995-08-11 | Floch Serge | Protège-seringue pour radioéléments émetteurs béta. |
| JP3591837B2 (ja) | 1994-02-17 | 2004-11-24 | ニューヨーク・ブラッド・センター・インコーポレイテッド | フィブリン膠およびリポソームを含有する生物学的生体接着剤組成物、その製造方法および使用 |
| US6334872B1 (en) | 1994-02-18 | 2002-01-01 | Organogenesis Inc. | Method for treating diseased or damaged organs |
| DE4408108A1 (de) | 1994-03-10 | 1995-09-14 | Bavaria Med Tech | Katheter zur Injektion eines Fluid bzw. eines Arneimittelns |
| US5464395A (en) | 1994-04-05 | 1995-11-07 | Faxon; David P. | Catheter for delivering therapeutic and/or diagnostic agents to the tissue surrounding a bodily passageway |
| DE69535752D1 (de) | 1994-04-13 | 2008-06-26 | Biotransplant Inc | Alpha(1,3)galactosyltransferase-negatives schwein |
| ATE219343T1 (de) | 1994-04-29 | 2002-07-15 | Scimed Life Systems Inc | Stent mit kollagen |
| US6056744A (en) | 1994-06-24 | 2000-05-02 | Conway Stuart Medical, Inc. | Sphincter treatment apparatus |
| US5621610A (en) | 1994-06-30 | 1997-04-15 | Compaq Computer Corporation | Collapsible computer keyboard structure with associated collapsible pointing stick |
| US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| IL110367A (en) | 1994-07-19 | 2007-05-15 | Colbar Lifescience Ltd | Collagen-based matrix |
| US6152141A (en) | 1994-07-28 | 2000-11-28 | Heartport, Inc. | Method for delivery of therapeutic agents to the heart |
| US5516532A (en) | 1994-08-05 | 1996-05-14 | Children's Medical Center Corporation | Injectable non-immunogenic cartilage and bone preparation |
| US5740808A (en) | 1996-10-28 | 1998-04-21 | Ep Technologies, Inc | Systems and methods for guilding diagnostic or therapeutic devices in interior tissue regions |
| WO1996011671A1 (en) | 1994-10-12 | 1996-04-25 | Focal, Inc. | Targeted delivery via biodegradable polymers |
| US6099864A (en) | 1994-12-02 | 2000-08-08 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | In situ activation of microcapsules |
| FR2727692A1 (fr) | 1994-12-05 | 1996-06-07 | Europ Propulsion | Dispositif d'extraction de gaz pour four d'infiltration ou depot chimique en phase vapeur dans une installation de fabrication de pieces en materiau composite |
| US5810885A (en) | 1994-12-28 | 1998-09-22 | Omrix Biopharm Sa | Device for applying one or several fluids |
| US5919570A (en) | 1995-02-01 | 1999-07-06 | Schneider Inc. | Slippery, tenaciously adhering hydrogel coatings containing a polyurethane-urea polymer hydrogel commingled with a poly(N-vinylpyrrolidone) polymer hydrogel, coated polymer and metal substrate materials, and coated medical devices |
| US5551427A (en) | 1995-02-13 | 1996-09-03 | Altman; Peter A. | Implantable device for the effective elimination of cardiac arrhythmogenic sites |
| US5869127A (en) | 1995-02-22 | 1999-02-09 | Boston Scientific Corporation | Method of providing a substrate with a bio-active/biocompatible coating |
| US5580714A (en) | 1995-03-08 | 1996-12-03 | Celox Laboratories, Inc. | Cryopreservation solution |
| US5906934A (en) * | 1995-03-14 | 1999-05-25 | Morphogen Pharmaceuticals, Inc. | Mesenchymal stem cells for cartilage repair |
| US5554389A (en) | 1995-04-07 | 1996-09-10 | Purdue Research Foundation | Urinary bladder submucosa derived tissue graft |
| US5669883A (en) | 1995-04-12 | 1997-09-23 | Symbiosis Corporation | Veress needle and cannula assembly |
| US6251104B1 (en) | 1995-05-10 | 2001-06-26 | Eclipse Surgical Technologies, Inc. | Guiding catheter system for ablating heart tissue |
| US5919449A (en) | 1995-05-30 | 1999-07-06 | Diacrin, Inc. | Porcine cardiomyocytes and their use in treatment of insufficient cardiac function |
| US5900433A (en) | 1995-06-23 | 1999-05-04 | Cormedics Corp. | Vascular treatment method and apparatus |
| US5693029A (en) | 1995-07-10 | 1997-12-02 | World Medical Manufacturing Corporation | Pro-cell intra-cavity therapeutic agent delivery device |
| US6102904A (en) | 1995-07-10 | 2000-08-15 | Interventional Technologies, Inc. | Device for injecting fluid into a wall of a blood vessel |
| US6143211A (en) | 1995-07-21 | 2000-11-07 | Brown University Foundation | Process for preparing microparticles through phase inversion phenomena |
| AU7254896A (en) | 1995-10-05 | 1997-04-28 | Genentech Inc. | Improved angiogenesis using hepatocyte growth factor |
| IL124038A (en) | 1995-10-13 | 2004-02-19 | Transvascular Inc | Apparatus for bypassing arterial obstructions and/or performing other transvascular procedures |
| US6726677B1 (en) | 1995-10-13 | 2004-04-27 | Transvascular, Inc. | Stabilized tissue penetrating catheters |
| US5642234A (en) | 1995-10-30 | 1997-06-24 | Lumatec Industries, Inc. | Illuminated magnifying lens assembly |
| US6482231B1 (en) | 1995-11-20 | 2002-11-19 | Giovanni Abatangelo | Biological material for the repair of connective tissue defects comprising mesenchymal stem cells and hyaluronic acid derivative |
| US6458889B1 (en) | 1995-12-18 | 2002-10-01 | Cohesion Technologies, Inc. | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
| EP1704878B1 (en) | 1995-12-18 | 2013-04-10 | AngioDevice International GmbH | Crosslinked polymer compositions and methods for their use |
| US5941868A (en) | 1995-12-22 | 1999-08-24 | Localmed, Inc. | Localized intravascular delivery of growth factors for promotion of angiogenesis |
| US6632436B2 (en) | 1996-01-25 | 2003-10-14 | Genitrix Llc | Vaccine compositions and method of modulating immune responses |
| AU715822B2 (en) | 1996-03-15 | 2000-02-10 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Tissue adhesive suitable for spray application |
| AU737078C (en) | 1996-05-24 | 2002-05-02 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating or preventing diseases of body passageways |
| EP0907721A1 (en) | 1996-05-28 | 1999-04-14 | Brown University Research Foundation | Hyaluronan based biodegradable scaffolds for tissue repair |
| US5785689A (en) | 1996-07-18 | 1998-07-28 | Act Medical, Inc. | Endoscopic catheter sheath position control |
| US5655548A (en) | 1996-09-16 | 1997-08-12 | Circulation, Inc. | Method for treatment of ischemic heart disease by providing transvenous myocardial perfusion |
| US5957941A (en) | 1996-09-27 | 1999-09-28 | Boston Scientific Corporation | Catheter system and drive assembly thereof |
| US5827313A (en) | 1996-09-27 | 1998-10-27 | Boston Scientific Corporation | Device for controlled longitudinal movement of an operative element within a catheter sheath and method |
| US5722403A (en) | 1996-10-28 | 1998-03-03 | Ep Technologies, Inc. | Systems and methods using a porous electrode for ablating and visualizing interior tissue regions |
| US5980887A (en) | 1996-11-08 | 1999-11-09 | St. Elizabeth's Medical Center Of Boston | Methods for enhancing angiogenesis with endothelial progenitor cells |
| EP0842640A1 (de) | 1996-11-13 | 1998-05-20 | Sulzer Osypka GmbH | Herzkatheter mit Elektrode auf aufspannbarer Einrichtung |
| ZA9710342B (en) | 1996-11-25 | 1998-06-10 | Alza Corp | Directional drug delivery stent and method of use. |
| US6120520A (en) | 1997-05-27 | 2000-09-19 | Angiotrax, Inc. | Apparatus and methods for stimulating revascularization and/or tissue growth |
| US6102926A (en) | 1996-12-02 | 2000-08-15 | Angiotrax, Inc. | Apparatus for percutaneously performing myocardial revascularization having means for sensing tissue parameters and methods of use |
| US5730732A (en) | 1996-12-04 | 1998-03-24 | Ethicon, Inc. | Non-magnetic stainless steel surgical needle |
| US5935160A (en) | 1997-01-24 | 1999-08-10 | Cardiac Pacemakers, Inc. | Left ventricular access lead for heart failure pacing |
| JP3134287B2 (ja) | 1997-01-30 | 2001-02-13 | 株式会社ニッショー | 心腔内縫合手術用カテーテル組立体 |
| US5980551A (en) | 1997-02-07 | 1999-11-09 | Endovasc Ltd., Inc. | Composition and method for making a biodegradable drug delivery stent |
| US5968064A (en) | 1997-02-28 | 1999-10-19 | Lumend, Inc. | Catheter system for treating a vascular occlusion |
| US6045565A (en) | 1997-11-04 | 2000-04-04 | Scimed Life Systems, Inc. | Percutaneous myocardial revascularization growth factor mediums and method |
| US6093177A (en) | 1997-03-07 | 2000-07-25 | Cardiogenesis Corporation | Catheter with flexible intermediate section |
| US6443949B2 (en) | 1997-03-13 | 2002-09-03 | Biocardia, Inc. | Method of drug delivery to interstitial regions of the myocardium |
| US6416510B1 (en) | 1997-03-13 | 2002-07-09 | Biocardia, Inc. | Drug delivery catheters that attach to tissue and methods for their use |
| US6086582A (en) | 1997-03-13 | 2000-07-11 | Altman; Peter A. | Cardiac drug delivery system |
| WO1998043555A1 (en) | 1997-04-03 | 1998-10-08 | Point Biomedical Corporation | Intravesical drug delivery system |
| US5984908A (en) | 1997-04-10 | 1999-11-16 | Chase Medical Inc | Venous return catheter having integral support member |
| US6099832A (en) | 1997-05-28 | 2000-08-08 | Genzyme Corporation | Transplants for myocardial scars |
| DE19734220C2 (de) | 1997-08-07 | 2000-01-13 | Pulsion Verwaltungs Gmbh & Co | Kathetersystem mit einem Einführungsdraht |
| EP1009317A4 (en) | 1997-08-28 | 2001-01-24 | Boston Scient Corp | SYSTEM FOR IMPLANTING CROSSLINKED POLYSACCHARIDE FIBER AND METHODS OF FORMING AND INSERTING THE SAME |
| WO1999011287A1 (en) | 1997-09-04 | 1999-03-11 | Osiris Therapeutics, Inc. | Ligands that modulate differentiation of mesenchymal stem cells |
| US6050949A (en) | 1997-09-22 | 2000-04-18 | Scimed Life Systems, Inc. | Catheher system having connectable distal and proximal portions |
| US6183444B1 (en) | 1998-05-16 | 2001-02-06 | Microheart, Inc. | Drug delivery module |
| US6179809B1 (en) | 1997-09-24 | 2001-01-30 | Eclipse Surgical Technologies, Inc. | Drug delivery catheter with tip alignment |
| US6371935B1 (en) | 1999-01-22 | 2002-04-16 | Cardeon Corporation | Aortic catheter with flow divider and methods for preventing cerebral embolization |
| WO1999017784A1 (en) | 1997-10-07 | 1999-04-15 | Regents Of The University Of California Corporation | Treating occlusive peripheral vascular disease and coronary disease with combinations of heparin and an adenoside a2 agonist, or with adenosine |
| IL122153A (en) | 1997-11-10 | 2005-03-20 | Alomone Labs Ltd | Biocompatible polymeric coating material |
| US6146373A (en) | 1997-10-17 | 2000-11-14 | Micro Therapeutics, Inc. | Catheter system and method for injection of a liquid embolic composition and a solidification agent |
| US6391311B1 (en) | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
| US6458095B1 (en) | 1997-10-22 | 2002-10-01 | 3M Innovative Properties Company | Dispenser for an adhesive tissue sealant having a housing with multiple cavities |
| US6749617B1 (en) | 1997-11-04 | 2004-06-15 | Scimed Life Systems, Inc. | Catheter and implants for the delivery of therapeutic agents to tissues |
| US6151525A (en) | 1997-11-07 | 2000-11-21 | Medtronic, Inc. | Method and system for myocardial identifier repair |
| US6183432B1 (en) | 1997-11-13 | 2001-02-06 | Lumend, Inc. | Guidewire and catheter with rotating and reciprocating symmetrical or asymmetrical distal tip |
| US6197324B1 (en) | 1997-12-18 | 2001-03-06 | C. R. Bard, Inc. | System and methods for local delivery of an agent |
| US6371992B1 (en) | 1997-12-19 | 2002-04-16 | The Regents Of The University Of California | Acellular matrix grafts: preparation and use |
| US6217527B1 (en) | 1998-09-30 | 2001-04-17 | Lumend, Inc. | Methods and apparatus for crossing vascular occlusions |
| US6231546B1 (en) | 1998-01-13 | 2001-05-15 | Lumend, Inc. | Methods and apparatus for crossing total occlusions in blood vessels |
| US6187330B1 (en) | 1998-01-30 | 2001-02-13 | Scios Inc. | Controlled release delivery of peptide or protein |
| US6221425B1 (en) | 1998-01-30 | 2001-04-24 | Advanced Cardiovascular Systems, Inc. | Lubricious hydrophilic coating for an intracorporeal medical device |
| DE69838526T2 (de) | 1998-02-05 | 2008-07-03 | Biosense Webster, Inc., Diamond Bar | Gerät zum Freisetzen eines Medikaments im Herzen |
| EP0938871A3 (en) | 1998-02-27 | 2001-03-07 | ECLIPSE SURGICAL TECHNOLOGIES, Inc. | Surgical apparatus |
| US6201608B1 (en) | 1998-03-13 | 2001-03-13 | Optical Biopsy Technologies, Inc. | Method and apparatus for measuring optical reflectivity and imaging through a scattering medium |
| US6175669B1 (en) | 1998-03-30 | 2001-01-16 | The Regents Of The Universtiy Of California | Optical coherence domain reflectometry guidewire |
| IL138666A0 (en) | 1998-03-31 | 2001-10-31 | Transvascular Inc | Catheters, systems and methods for percutaneous in situ arterio-venous bypass |
| US5979449A (en) | 1998-04-09 | 1999-11-09 | Steer; Eugene Lyle | Oral appliance device and method for use thereof for appetite suppression |
| US6206914B1 (en) | 1998-04-30 | 2001-03-27 | Medtronic, Inc. | Implantable system with drug-eluting cells for on-demand local drug delivery |
| ATE358456T1 (de) | 1998-05-05 | 2007-04-15 | Boston Scient Ltd | Stent mit glatten enden |
| US6447504B1 (en) | 1998-07-02 | 2002-09-10 | Biosense, Inc. | System for treatment of heart tissue using viability map |
| US6613070B2 (en) | 1998-08-04 | 2003-09-02 | Baxter International Inc. | System and method for sealing vascular penetrations with hemostatic gels |
| US6102887A (en) | 1998-08-11 | 2000-08-15 | Biocardia, Inc. | Catheter drug delivery system and method for use |
| CA2339330A1 (en) | 1998-08-13 | 2000-02-24 | University Of Southern California | Methods to increase blood flow to ischemic tissue |
| US6632457B1 (en) | 1998-08-14 | 2003-10-14 | Incept Llc | Composite hydrogel drug delivery systems |
| US6191144B1 (en) | 1998-08-17 | 2001-02-20 | Warner-Lambert Company | Method of using angiotensin converting enzyme inhibitor to stimulate angiogenesis |
| CA2340652C (en) | 1998-08-20 | 2013-09-24 | Cook Incorporated | Coated implantable medical device comprising paclitaxel |
| JP2002524425A (ja) | 1998-09-04 | 2002-08-06 | サイオス インコーポレイテッド | 増殖因子の徐放性投与のためのヒドロゲル組成物 |
| US6044298A (en) | 1998-10-13 | 2000-03-28 | Cardiac Pacemakers, Inc. | Optimization of pacing parameters based on measurement of integrated acoustic noise |
| US6162202A (en) | 1998-10-26 | 2000-12-19 | Sicurelli; Robert | Flexible syringe needle |
| CA2349168C (en) | 1998-11-10 | 2009-01-06 | Denki Kagaku Kogyo Kabushiki Kaisha | Hyaluronic acid gel, method of its production and medical material containing it |
| US6761887B1 (en) | 1998-11-16 | 2004-07-13 | Osiris Therapeutics, Inc. | Alginate layer system for chondrogenic differentiation of human mesenchymal stem cells |
| DE19855890A1 (de) | 1998-12-03 | 2000-06-08 | Nerlich Michael | Poröse Kompositmatrix, deren Herstellung und Verwendung |
| KR20010040761A (ko) | 1998-12-09 | 2001-05-15 | 쿡 인코포레이티드 | 중공의 만곡형 초탄성 의료용 니들 |
| US6193763B1 (en) | 1998-12-17 | 2001-02-27 | Robert A. Mackin | Apparatus and method for contemporaneous treatment and fluoroscopic mapping of body tissue |
| US6328229B1 (en) | 1998-12-18 | 2001-12-11 | Cohesion Technologies, Inc. | Low volume mixing spray head for mixing and dispensing of two reactive fluid components |
| US6338717B1 (en) | 1998-12-22 | 2002-01-15 | Asahi Kogaku Kogyo Kabushiki Kaisha | Tip of ultrasonic endoscope |
| US6210392B1 (en) | 1999-01-15 | 2001-04-03 | Interventional Technologies, Inc. | Method for treating a wall of a blood vessel |
| WO2000041732A1 (en) | 1999-01-19 | 2000-07-20 | The Children's Hospital Of Philadelphia | Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof |
| US6217554B1 (en) | 1999-02-12 | 2001-04-17 | Pharmaspec Corporation | Methods and apparatus for delivering substances into extravascular tissue |
| US20020081732A1 (en) | 2000-10-18 | 2002-06-27 | Bowlin Gary L. | Electroprocessing in drug delivery and cell encapsulation |
| US7615373B2 (en) | 1999-02-25 | 2009-11-10 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed collagen and tissue engineering |
| US20020090725A1 (en) | 2000-11-17 | 2002-07-11 | Simpson David G. | Electroprocessed collagen |
| US6777231B1 (en) | 1999-03-10 | 2004-08-17 | The Regents Of The University Of California | Adipose-derived stem cells and lattices |
| US6432119B1 (en) | 1999-03-17 | 2002-08-13 | Angiotrax, Inc. | Apparatus and methods for performing percutaneous myocardial revascularization and stimulating angiogenesis using autologous materials |
| US6296602B1 (en) | 1999-03-17 | 2001-10-02 | Transfusion Technologies Corporation | Method for collecting platelets and other blood components from whole blood |
| JP3678602B2 (ja) | 1999-03-17 | 2005-08-03 | 住友ベークライト株式会社 | シリンジ固定注入装置 |
| US6312725B1 (en) | 1999-04-16 | 2001-11-06 | Cohesion Technologies, Inc. | Rapid gelling biocompatible polymer composition |
| US6192271B1 (en) | 1999-04-20 | 2001-02-20 | Michael Hayman | Radiotherapy stent |
| US6858229B1 (en) | 1999-04-26 | 2005-02-22 | California Institute Of Technology | In situ forming hydrogels |
| US6159443A (en) | 1999-04-29 | 2000-12-12 | Vanderbilt University | X-ray guided drug delivery |
| US6494862B1 (en) | 1999-07-13 | 2002-12-17 | Advanced Cardiovascular Systems, Inc. | Substance delivery apparatus and a method of delivering a therapeutic substance to an anatomical passageway |
| US6283947B1 (en) | 1999-07-13 | 2001-09-04 | Advanced Cardiovascular Systems, Inc. | Local drug delivery injection catheter |
| US7815590B2 (en) | 1999-08-05 | 2010-10-19 | Broncus Technologies, Inc. | Devices for maintaining patency of surgically created channels in tissue |
| US6358258B1 (en) | 1999-09-14 | 2002-03-19 | Abbott Laboratories | Device and method for performing end-to-side anastomosis |
| US6385476B1 (en) | 1999-09-21 | 2002-05-07 | Biosense, Inc. | Method and apparatus for intracardially surveying a condition of a chamber of a heart |
| DE60008001T2 (de) | 1999-09-21 | 2004-09-02 | Institut De Cardiologie De Montreal, Montreal | Lokale verabreichung von 17-beta estradiol zur verbesserung der vaskularen endothelialen funktion nach gefässverletzungen |
| US6368285B1 (en) | 1999-09-21 | 2002-04-09 | Biosense, Inc. | Method and apparatus for mapping a chamber of a heart |
| US20040229856A1 (en) | 1999-09-21 | 2004-11-18 | Baskaran Chandrasekar | Local delivery of 17-beta estradiol for preventing vascular intimal hyperplasia and for improving vascular endothelium function after vascular injury |
| US6916488B1 (en) | 1999-11-05 | 2005-07-12 | Biocure, Inc. | Amphiphilic polymeric vesicles |
| US6748258B1 (en) | 1999-11-05 | 2004-06-08 | Scimed Life Systems, Inc. | Method and devices for heart treatment |
| US6992172B1 (en) | 1999-11-12 | 2006-01-31 | Fibrogen, Inc. | Recombinant gelatins |
| US6360129B1 (en) | 1999-12-13 | 2002-03-19 | Cardiac Pacemakers, Inc. | Mannitol/hydrogel cap for tissue-insertable connections |
| US6241710B1 (en) | 1999-12-20 | 2001-06-05 | Tricardia Llc | Hypodermic needle with weeping tip and method of use |
| US6706034B1 (en) | 1999-12-30 | 2004-03-16 | Advanced Cardiovascular Systems, Inc. | Process for agent retention in biological tissues |
| US6547806B1 (en) | 2000-02-04 | 2003-04-15 | Ni Ding | Vascular sealing device and method of use |
| US6346098B1 (en) | 2000-03-07 | 2002-02-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and kits for locally administering an active agent to an interstitial space of a host |
| AUPQ618400A0 (en) | 2000-03-13 | 2000-04-06 | Baramy Engineering Pty Ltd | A gross pollutant trap |
| US6458098B1 (en) | 2000-03-17 | 2002-10-01 | Nozomu Kanesaka | Vascular therapy device |
| US6478776B1 (en) | 2000-04-05 | 2002-11-12 | Biocardia, Inc. | Implant delivery catheter system and methods for its use |
| US6589549B2 (en) | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
| WO2002000173A2 (en) | 2000-06-26 | 2002-01-03 | Rxkinetix, Inc. | Methods for use of delivery composition for expanding, activating, committing or mobilizing one or more pluripotent, self-renewing and committed stem cells |
| US6548081B2 (en) | 2000-07-28 | 2003-04-15 | Anika Therapeutics, Inc. | Bioabsorbable composites of derivatized hyaluronic acid and other biodegradable, biocompatible polymers |
| US6478775B1 (en) | 2000-10-02 | 2002-11-12 | Genyx Medical Inc. | Device for delivering non-biodegradable bulking composition to a urological site |
| US6554801B1 (en) | 2000-10-26 | 2003-04-29 | Advanced Cardiovascular Systems, Inc. | Directional needle injection drug delivery device and method of use |
| US20020072706A1 (en) | 2000-12-11 | 2002-06-13 | Thomas Hiblar | Transluminal drug delivery catheter |
| US6846319B2 (en) | 2000-12-14 | 2005-01-25 | Core Medical, Inc. | Devices for sealing openings through tissue and apparatus and methods for delivering them |
| US6692466B1 (en) | 2000-12-21 | 2004-02-17 | Advanced Cardiovascular Systems, Inc. | Drug delivery catheter with retractable needle |
| US6599267B1 (en) | 2000-12-22 | 2003-07-29 | Advanced Cardiovascular Systems, Inc. | Transluminal injection device for intravascular drug delivery |
| EP2314293B1 (en) | 2001-01-16 | 2017-01-04 | Vascular Therapies, LLC | Implantable device containing resorbable matrix material and rapamycin for preventing or treating vasuloproliferative diseases |
| US6602241B2 (en) | 2001-01-17 | 2003-08-05 | Transvascular, Inc. | Methods and apparatus for acute or chronic delivery of substances or apparatus to extravascular treatment sites |
| US6565530B2 (en) | 2001-02-28 | 2003-05-20 | Scimed Life Systems, Inc. | Immobilizing objects in the body |
| US6777000B2 (en) | 2001-02-28 | 2004-08-17 | Carrington Laboratories, Inc. | In-situ gel formation of pectin |
| WO2002067796A1 (en) | 2001-02-28 | 2002-09-06 | Rex Medical, L.P. | Apparatus for delivering ablation fluid to treat neoplasms |
| US20020124855A1 (en) | 2001-03-12 | 2002-09-12 | Chachques Juan C. | Method of providing a dynamic cellular cardiac support |
| US7029838B2 (en) | 2001-03-30 | 2006-04-18 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Prevascularized contructs for implantation to provide blood perfusion |
| US7396582B2 (en) | 2001-04-06 | 2008-07-08 | Advanced Cardiovascular Systems, Inc. | Medical device chemically modified by plasma polymerization |
| US7311731B2 (en) | 2001-04-27 | 2007-12-25 | Richard C. Satterfield | Prevention of myocardial infarction induced ventricular expansion and remodeling |
| US20020188170A1 (en) | 2001-04-27 | 2002-12-12 | Santamore William P. | Prevention of myocardial infarction induced ventricular expansion and remodeling |
| US6628988B2 (en) | 2001-04-27 | 2003-09-30 | Cardiac Pacemakers, Inc. | Apparatus and method for reversal of myocardial remodeling with electrical stimulation |
| US6660034B1 (en) | 2001-04-30 | 2003-12-09 | Advanced Cardiovascular Systems, Inc. | Stent for increasing blood flow to ischemic tissues and a method of using the same |
| US6702744B2 (en) | 2001-06-20 | 2004-03-09 | Advanced Cardiovascular Systems, Inc. | Agents that stimulate therapeutic angiogenesis and techniques and devices that enable their delivery |
| US6723067B2 (en) | 2001-07-26 | 2004-04-20 | David H. Nielson | Apparatus for delivering aerosolized fibrin endoscopically to a wound |
| CA2456806C (en) | 2001-08-08 | 2011-10-18 | Brown University Research Foundation | Methods for micronization of hydrophobic drugs |
| US6663596B2 (en) | 2001-08-13 | 2003-12-16 | Scimed Life Systems, Inc. | Delivering material to a patient |
| JP2003062089A (ja) | 2001-08-24 | 2003-03-04 | Sumitomo Bakelite Co Ltd | 医療用コネクター |
| ITVR20010098A1 (it) | 2001-09-11 | 2003-03-11 | Consorzio Per Gli Studi Uni | Procedimento per l'ottenimento di idrogeli di fibroina di seta. |
| US7037289B2 (en) | 2001-09-12 | 2006-05-02 | 3M Innovative Properties Company | Apparatus and methods for dispensing an adhesive tissue sealant |
| US6790455B2 (en) | 2001-09-14 | 2004-09-14 | The Research Foundation At State University Of New York | Cell delivery system comprising a fibrous matrix and cells |
| US7112587B2 (en) | 2001-09-21 | 2006-09-26 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
| US6893431B2 (en) | 2001-10-15 | 2005-05-17 | Scimed Life Systems, Inc. | Medical device for delivering patches |
| EP1446453A1 (en) | 2001-11-07 | 2004-08-18 | Universität Zürich | Synthetic matrix for controlled cell ingrowth and tissue regeneration and endometriosis |
| US7035092B2 (en) | 2001-11-08 | 2006-04-25 | Apple Computer, Inc. | Computer controlled display device |
| US8608661B1 (en) | 2001-11-30 | 2013-12-17 | Advanced Cardiovascular Systems, Inc. | Method for intravascular delivery of a treatment agent beyond a blood vessel wall |
| US6973349B2 (en) | 2001-12-05 | 2005-12-06 | Cardiac Pacemakers, Inc. | Method and apparatus for minimizing post-infarct ventricular remodeling |
| US7169127B2 (en) | 2002-02-21 | 2007-01-30 | Boston Scientific Scimed, Inc. | Pressure apron direct injection catheter |
| JP4229621B2 (ja) | 2002-03-05 | 2009-02-25 | 修 加藤 | 薬液注入カテーテル |
| WO2003079985A2 (en) | 2002-03-18 | 2003-10-02 | Carnegie Mellon University | Method and apparatus for preparing biomimetic scaffold |
| CA2525994C (en) | 2002-06-24 | 2012-10-16 | Tufts University | Silk biomaterials and methods of use thereof |
| US7361368B2 (en) | 2002-06-28 | 2008-04-22 | Advanced Cardiovascular Systems, Inc. | Device and method for combining a treatment agent and a gel |
| US7008411B1 (en) | 2002-09-30 | 2006-03-07 | Advanced Cardiovascular Systems, Inc. | Method and apparatus for treating vulnerable plaque |
| US7438692B2 (en) | 2002-10-18 | 2008-10-21 | Mark Tsonton | Localization mechanism for an MRI compatible biopsy device |
| CA2511521C (en) * | 2002-12-30 | 2012-02-07 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
| US7393339B2 (en) | 2003-02-21 | 2008-07-01 | C. R. Bard, Inc. | Multi-lumen catheter with separate distal tips |
| US20050015048A1 (en) | 2003-03-12 | 2005-01-20 | Chiu Jessica G. | Infusion treatment agents, catheters, filter devices, and occlusion devices, and use thereof |
| US7250041B2 (en) | 2003-03-12 | 2007-07-31 | Abbott Cardiovascular Systems Inc. | Retrograde pressure regulated infusion |
| US8038991B1 (en) | 2003-04-15 | 2011-10-18 | Abbott Cardiovascular Systems Inc. | High-viscosity hyaluronic acid compositions to treat myocardial conditions |
| US8383158B2 (en) | 2003-04-15 | 2013-02-26 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
| MXPA05011896A (es) | 2003-05-05 | 2006-05-25 | Univ Ben Gurion | Preparaciones polimericas reticuladas inyectables y sus usos. |
| WO2005010172A2 (en) | 2003-07-16 | 2005-02-03 | Boston Scientific Limited | Aligned scaffolds for improved myocardial regeneration |
| US7129210B2 (en) * | 2003-07-23 | 2006-10-31 | Covalent Medical, Inc. | Tissue adhesive sealant |
| US7169404B2 (en) * | 2003-07-30 | 2007-01-30 | Advanced Cardiovasular Systems, Inc. | Biologically absorbable coatings for implantable devices and methods for fabricating the same |
| CA2535346A1 (en) | 2003-08-13 | 2005-03-03 | Medtronic, Inc. | Active agent delivery systems, including a single layer of a miscible polymer blend, medical devices, and methods |
| US7998112B2 (en) | 2003-09-30 | 2011-08-16 | Abbott Cardiovascular Systems Inc. | Deflectable catheter assembly and method of making same |
| KR20060130580A (ko) | 2003-12-10 | 2006-12-19 | 셀룰라 바이오엔지니어링 인코포레이티드 | 연조직 형태 복원을 위한 조성물 및 방법 |
| US7273469B1 (en) | 2003-12-31 | 2007-09-25 | Advanced Cardiovascular Systems, Inc. | Modified needle catheter for directional orientation delivery |
| US20050186240A1 (en) * | 2004-02-23 | 2005-08-25 | Ringeisen Timothy A. | Gel suitable for implantation and delivery system |
| US8067031B2 (en) | 2004-04-28 | 2011-11-29 | Angiodevice International Gmbh | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
| GB0419653D0 (en) | 2004-09-04 | 2004-10-06 | Psimedica Ltd | Needle assembly |
| US20060149392A1 (en) | 2004-12-07 | 2006-07-06 | Kuo-Huang Hsieh | Biomaterials for guided tissue regeneration and drug delivery |
| US7854944B2 (en) | 2004-12-17 | 2010-12-21 | Advanced Cardiovascular Systems, Inc. | Tissue regeneration |
| US8187621B2 (en) | 2005-04-19 | 2012-05-29 | Advanced Cardiovascular Systems, Inc. | Methods and compositions for treating post-myocardial infarction damage |
| US8828433B2 (en) * | 2005-04-19 | 2014-09-09 | Advanced Cardiovascular Systems, Inc. | Hydrogel bioscaffoldings and biomedical device coatings |
| US8303972B2 (en) | 2005-04-19 | 2012-11-06 | Advanced Cardiovascular Systems, Inc. | Hydrogel bioscaffoldings and biomedical device coatings |
| JP4762785B2 (ja) * | 2005-06-02 | 2011-08-31 | 西川ゴム工業株式会社 | ゼラチンスポンジ |
| EP2623116A1 (en) | 2005-07-27 | 2013-08-07 | Eli Lilly and Company | A method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response |
| US7732190B2 (en) | 2006-07-31 | 2010-06-08 | Advanced Cardiovascular Systems, Inc. | Modified two-component gelation systems, methods of use and methods of manufacture |
| US9005672B2 (en) | 2006-11-17 | 2015-04-14 | Abbott Cardiovascular Systems Inc. | Methods of modifying myocardial infarction expansion |
| US8192760B2 (en) | 2006-12-04 | 2012-06-05 | Abbott Cardiovascular Systems Inc. | Methods and compositions for treating tissue using silk proteins |
| US8221744B2 (en) | 2007-09-19 | 2012-07-17 | Abbott Cardiovascular Systems Inc. | Cytocompatible alginate gels |
-
2006
- 2006-12-04 US US11/566,643 patent/US8192760B2/en not_active Expired - Fee Related
-
2007
- 2007-11-16 WO PCT/US2007/024158 patent/WO2008069919A2/en not_active Ceased
- 2007-11-16 JP JP2009539265A patent/JP5823094B2/ja not_active Expired - Fee Related
- 2007-11-16 EP EP07870900.3A patent/EP2099509B1/en active Active
-
2012
- 2012-05-15 US US13/472,328 patent/US8465773B2/en not_active Expired - Fee Related
- 2012-05-15 US US13/472,324 patent/US8465772B2/en not_active Expired - Fee Related
-
2013
- 2013-05-06 US US13/888,143 patent/US8828436B2/en not_active Expired - Fee Related
-
2014
- 2014-04-02 JP JP2014076351A patent/JP5853045B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010511426A (ja) | 2010-04-15 |
| EP2099509B1 (en) | 2016-09-21 |
| JP2014121652A (ja) | 2014-07-03 |
| US20120225041A1 (en) | 2012-09-06 |
| US8465773B2 (en) | 2013-06-18 |
| JP5853045B2 (ja) | 2016-02-09 |
| US20080131509A1 (en) | 2008-06-05 |
| US8192760B2 (en) | 2012-06-05 |
| US20130251764A1 (en) | 2013-09-26 |
| US20120225040A1 (en) | 2012-09-06 |
| EP2099509A2 (en) | 2009-09-16 |
| WO2008069919A3 (en) | 2008-10-09 |
| US8465772B2 (en) | 2013-06-18 |
| US8828436B2 (en) | 2014-09-09 |
| WO2008069919A2 (en) | 2008-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5853045B2 (ja) | 絹タンパク質を使用する組織の治療方法及び組成物 | |
| US8486387B2 (en) | Modified two-component gelation systems, methods of use and methods of manufacture | |
| US8609126B2 (en) | Methods and compositions for treating post-myocardial infarction damage | |
| JP5313154B2 (ja) | 変性二成分ゲル化系、使用方法および製造方法 | |
| US8303972B2 (en) | Hydrogel bioscaffoldings and biomedical device coatings | |
| US9687630B2 (en) | Methods and compositions for treating post-cardial infarction damage | |
| US20080138416A1 (en) | Method and systems for using biopolymer-based beads and hydrogels | |
| Wang et al. | Hydrogels for cardiac repair | |
| HK1169043A (en) | Modified two-component gelation systems, methods of use and methods of manufacture |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101116 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101116 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121119 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130219 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130325 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130625 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130702 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130724 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140402 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140417 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140422 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20140530 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150714 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151007 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5823094 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |